On Monday, Shares of Advanced Micro Devices, Inc. (NASDAQ:AMD), gained 0.43% to $2.32.
On May 6, at its 2015 Financial Analyst Day taking place at NASDAQ MarketSite, AMD (NASDAQ:AMD) offered details on the company’s multi-year strategy to drive profitable growth based on delivering next-generation technologies powering a broad set of high-performance, differentiated products across the key areas of gaming, immersive platforms, and the datacenter.
“We see strong long-term growth opportunities across a diverse set of markets for the kind of high-performance compute and visualization capabilities only AMD can provide,” said AMD President and CEO Dr. Lisa Su. “We are focusing our investments on our strongest opportunities to enable our customers to create great products that push the boundaries of what is possible and allow AMD to achieve profitable growth in the years to come.”
Advanced Micro Devices, Inc. operates as a semiconductor company worldwide. The company’s products primarily comprise x86 microprocessors as an accelerated processing unit (APU), chipsets, discrete graphics processing units (GPUs), and semi-custom System-on-Chip (SoC) products.
Shares of Hercules Offshore, Inc. (NASDAQ:HERO), inclined 3.03% to $0.99, during its last trading session.
On April 30, Hercules Offshore, declared that it has received a notice from Saudi Aramco extending the termination date of its drilling contract for the Hercules 261, to May 31, 2015.
Hercules Offshore, Inc., together with its auxiliaries, provides shallow-water drilling and marine services to the oil and natural gas exploration and production industry worldwide. The company operates through Domestic Offshore, International Offshore, and International Liftboats segments.
At the end of Monday’s trade, Shares of Bloomin’ Brands, Inc. (NASDAQ:BLMN), gained 2.68% to $22.01.
Bloomin Brands, stated financial results for the first quarter ended March 29, 2015 contrast to the first quarter ended March 30, 2014.
Key highlights for Q1 2015 comprise the following:
- Comparable sales for Company-owned U.S. concepts raised 3.6% with a traffic enhance of 0.7%
- Comparable sales for our Brazilian Outback Steakhouse restaurants raised 6.2%
- System-wide development was 14 new restaurants. In March 2015, we opened our first International Carrabba’s Italian Grill in Brazil, known as Abbraccio
- Adjusted operating income margin was 9.1% as compared to 8.4% in Q1 2014 and U.S. GAAP operating income margin was 8.1% as compared to 7.8% in the Q1 2014
- Adjusted net income was $69.7 million as compared to $58.5 million in Q1 2014 and U.S. GAAP Net income attributable to Bloomin’ Brands was $60.6 million as compared to $53.7 million in Q1 2014.
Bloomin Brands, Inc., through its auxiliaries, owns and operates casual, upscale casual, and fine dining restaurants primarily in the United States. The company operates restaurants under various concepts, counting Outback Steakhouse, a casual steakhouse restaurant; Carrabbas Italian Grill, a casual Italian restaurant; Bonefish Grill, an upscale casual seafood restaurant; and Fleming’s Prime Steakhouse & Wine Bar, a contemporary steakhouse.
Finally, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), ended its last trade with -2.12% loss, and closed at $4.15.
Arena Pharmaceuticals, offered a corporate update and stated financial results for the first quarter ended March 31, 2015.
BELVIQ® (lorcaserin HCl) Commercial Update
- IMS Health estimates that about 169,000 prescriptions for BELVIQ were filled in the United States in the first quarter of 2015, representing growth in total prescriptions of about 13.7% contrast to the previous quarter.
- Eisai recorded net US product sales for BELVIQ of $12.8 million during the first quarter of 2015.
- BELVIQ was approved for marketing for weight administration in South Korea, and Ildong commenced marketing in late February 2015. In connection with the approval, Arena received a milestone payment of $3.0 million from Ildong. From launch through March 31, patients filled prescriptions totaling 766,350 tablets, which equates to about 12,770 one-month prescriptions. Arena recorded $2.2 million net South Korea product sales for BELVIQ during the first quarter of 2015.
- Declared that the US Patent and Trademark Office granted Arena US Patent No. 8,999,970 for BELVIQ, which describes a method for selecting appropriate patients based on renal function. Arena anticipates this additional patent to potentially extend the exclusivity of BELVIQ until 2033.
Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors. The company offers BELVIQ, a drug used to treat chronic weight administration in adults.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
